Studying Factors That Predict Results of Drug-Coated Balloon Heart Procedures
Follows adults with coronary artery disease treated with a paclitaxel drug-coated balloon.
Plain-language title generated from the registry record
Registry title: Influencing Factors and Outcomes of DCB Angioplasty
Key facts
- Where
- Zhengzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with coronary artery disease who are scheduled to have paclitaxel drug-coated balloon angioplasty.
- Age
- 18 years and older
- Sex
- All sexes can join
- Disease stage
- Coronary artery disease with lesions in native large vessels, confirmed by coronary angiography. Heart function NYHA I-III.
- Earlier treatment
- Scheduled to receive paclitaxel drug-coated balloon angioplasty. Cannot be in another clinical trial that might affect the results.
Main reasons for not taking part
- Known allergy to paclitaxel or to materials used in angioplasty, such as contrast agents
- Uncontrolled high blood pressure (systolic above 180 mmHg or diastolic above 110 mmHg)
- Active bleeding or clotting disorder
- Other serious disease with a life expectancy of less than 1 year
- Pregnant or breastfeeding
Read by machine on 12 November 2026.
Where in China
- Fuwai Central China Cardiovascular HospitalZhengzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Henan Institute of Cardiovascular Epidemiology
- Trial code
- NCT06620458
- Record updated
- 9 October 2026
- Original description
This ambiprospective observational study evaluates the long-term safety and efficacy of Paclitaxel Drug-Coated Balloon (DCB) angioplasty in approximately 20,000 patients withcoronary artery lesions in large vessels. By combining retrospective historical data with a prospective registry involving biological specimen collection, the study aims to identify key predictors of outcomes, including intravascular imaging findings, hemodynamic parameters, and biological markers. Patients will be followed longitudinally for up to 10 years to assess the durability of the treatment and the incidence of major adverse cardiovascular events (MACE).Read full original descriptionShow less
Analysis of Prognostic Factors for Drug-Coated Balloon Angioplasty in Patients With Coronary Artery Disease: An Ambiprospective Cohort Study
This ambiprospective observational study evaluates the long-term safety and efficacy of Paclitaxel Drug-Coated Balloon (DCB) angioplasty in approximately 20,000 patients withcoronary artery lesions in large vessels. By combining retrospective historical data with a prospective registry involving biological specimen collection, the study aims to identify key predictors of outcomes, including intravascular imaging findings, hemodynamic parameters, and biological markers. Patients will be followed longitudinally for up to 10 years to assess the durability of the treatment and the incidence of major adverse cardiovascular events (MACE).
Inclusion: Age:; 18 years and older; Diagnosis:; Diagnosed with coronary artery disease with native large vessel lesions confirmed by coronary angiography; Treatment Plan:; Scheduled to receive paclitaxel drug-coated balloon angioplasty; Informed Consent:; Patients have been fully informed about the nature and purpose of the study, and have voluntarily agreed to participate, with signed informed consent; Physiological Status:; Cardiac function classified as NYHA I-III.
Exclusion: Allergy History:; Known allergies to paclitaxel or any materials used in angioplasty (e.g., contrast agents); Severe Complications:; Uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg); Other Medical Conditions:; Active bleeding or clotting disorders; Other serious diseases with a life expectancy of less than 1 year (e.g., advanced cancer); Psychological or Behavioral Factors: History of psychiatric or behavioral disorders that could interfere with adherence to study protocols, or communication barriers that prevent understanding of study requirements; Pregnancy or Nursing: Women who are currently pregnant or breastfeeding; Participation in Other Studies: Currently participating in other clinical trials that might affect the results of this study.